Avantra Changes Name to Courtagen as Part of Expansion into Genomic Tools Market | GenomeWeb

By Justin Petrone

Avantra Biosciences this week changed its name to Courtagen Life Sciences in order to better reflect the firm's desire to move beyond the proteomics market and into other application areas, according to company officials.

"The name change reflects the company's new strategic focus on developing advanced technologies in both genomic and proteomic areas, and our commitment to bring additional needed technologies to the market," said CEO Brian McKernan in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.